Stop Overstocking Branded Drugs—Before It Becomes a Margin Problem
Branded drug inventory risk doesn’t announce itself. It shows up quietly—then suddenly.
A wholesaler buys inventory expecting stable demand, only to face a wave of unexpected pricing pr…

Big Pharma doesn’t just “plan for the future.” It signals it—quietly—through who it hires, who it stops hiring, and how quickly it reshuffles teams when patent cliffs hit.
If you want to understand workforce shifts in life sciences, don’t start with he…

Biosimilar switching isn’t a procurement problem—it’s a patent strategy problem.
If you’re planning a biosimilar switch, you’re probably thinking about pricing, contracting, and supply. Those matter. But the real question is simpler—and harder:
When ca…

Pharma has a new playbook—and it’s not always about new science.
In a world where patients are increasingly asked to pay more for less, the industry’s most controversial strategy is quietly taking center stage: repurposed drugs—old molecules with new i…

Pharma hiring is broken in a very specific way.
Recruiters often chase the loudest signals—titles, conference appearances, “years of experience,” maybe a keyword match on a resume. But in drug development, the most valuable signal is usually quieter: w…

Pharma has a familiar playbook for “new” prices: take an old drug, reframe the story, and sell the premium as progress.
That’s the tension at the heart of Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines—a topic that…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” is becoming the main engine. Here’s what patent filings are quietly signaling about APIs and full-cycle drug production.
If you’ve ever heard the phrase “the third wheel rule” in the context of Russia’s industrial policy, you mig…

Big Pharma doesn’t always “win” in court. Sometimes it just… never lets the case end.
Europe’s divisional patent game—where companies strategically split patent applications to keep disputes alive—has become a quiet but powerful tool to delay final dec…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a controllable line item—one that can be cut to ~$5M with the right strategy, timing, and discipline.
That’s the core message behind a new playbook from DrugPatentWatch: h…